tetano
Editor, Senior Moderator
Int J Infect Dis
. 2023 Aug 10;S1201-9712(23)00694-X.
doi: 10.1016/j.ijid.2023.08.009. Online ahead of print. Vaccine-induced and hybrid immunity to SARS-CoV-2 after three or four doses of BNT162b2 - results from 22 months follow-up of a healthcare workers cohort, Israel, 2020-2022
Michael Edelstein[SUP] 1 [/SUP], Karine Wiegler Beiruti[SUP] 2 [/SUP], Hila Ben-Amram[SUP] 2 [/SUP], Netta Beer[SUP] 2 [/SUP], Christian Sussan[SUP] 2 [/SUP], Perachel Batya[SUP] 2 [/SUP], Salman Zarka[SUP] 3 [/SUP], Kamal Abu Jabal[SUP] 3 [/SUP]
Affiliations
Objective: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains a global health concern three years after its emergence. Safe and effective vaccines mitigate the pandemic impact but the optimal schedule remains unclear especially in a context where a high proportion of the population was infected.
Methods: We periodically measured anti-spike SARS-CoV-2 IgG titers using a quantitative assay in an Israeli healthcare worker cohort who all received at least two BNT162b2 doses and either received further doses and/or were subsequently infected, up to 22 months post-dose two, and compared geometric mean concentrations according to number of doses received and infection status using ANOVA.
Results: Among the 993 included participants, infection post-dose two led to higher GMC IgG titers than a third dose (4285 vs 2845 AU/ml one-two months post-infection/vaccination, p=0.03). 16-18 months post-dose two, those infected and those who received three or four vaccine doses all had IgG GMC levels above 500 AU/ml with no significant differences among groups (p=0.6). IgG levels plateaued 16-22 months post-dose 2.
Conclusion: Three BNT162b2 doses provide long-term immunogenicity comparable to breakthrough infection post-dose two. Dose four transiently increases IgG levels and may be especially important for providing additional protection to vulnerable individuals during periods of increased transmission risk.
Keywords: COVID-19; Israel; SARS-CoV-2; immunogenicity; vaccination; vaccines.
. 2023 Aug 10;S1201-9712(23)00694-X.
doi: 10.1016/j.ijid.2023.08.009. Online ahead of print. Vaccine-induced and hybrid immunity to SARS-CoV-2 after three or four doses of BNT162b2 - results from 22 months follow-up of a healthcare workers cohort, Israel, 2020-2022
Michael Edelstein[SUP] 1 [/SUP], Karine Wiegler Beiruti[SUP] 2 [/SUP], Hila Ben-Amram[SUP] 2 [/SUP], Netta Beer[SUP] 2 [/SUP], Christian Sussan[SUP] 2 [/SUP], Perachel Batya[SUP] 2 [/SUP], Salman Zarka[SUP] 3 [/SUP], Kamal Abu Jabal[SUP] 3 [/SUP]
Affiliations
- PMID: 37572957
- DOI: 10.1016/j.ijid.2023.08.009
Objective: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains a global health concern three years after its emergence. Safe and effective vaccines mitigate the pandemic impact but the optimal schedule remains unclear especially in a context where a high proportion of the population was infected.
Methods: We periodically measured anti-spike SARS-CoV-2 IgG titers using a quantitative assay in an Israeli healthcare worker cohort who all received at least two BNT162b2 doses and either received further doses and/or were subsequently infected, up to 22 months post-dose two, and compared geometric mean concentrations according to number of doses received and infection status using ANOVA.
Results: Among the 993 included participants, infection post-dose two led to higher GMC IgG titers than a third dose (4285 vs 2845 AU/ml one-two months post-infection/vaccination, p=0.03). 16-18 months post-dose two, those infected and those who received three or four vaccine doses all had IgG GMC levels above 500 AU/ml with no significant differences among groups (p=0.6). IgG levels plateaued 16-22 months post-dose 2.
Conclusion: Three BNT162b2 doses provide long-term immunogenicity comparable to breakthrough infection post-dose two. Dose four transiently increases IgG levels and may be especially important for providing additional protection to vulnerable individuals during periods of increased transmission risk.
Keywords: COVID-19; Israel; SARS-CoV-2; immunogenicity; vaccination; vaccines.